P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS

• A. McDonald,
• J. L. R. Malherbe,
• A. Kulasekararaj,
• W. Füreder,
• M. Griffin,
• M. Cornpropst,
• M. K. Farmer,
• D. Kargl,
• D. Collins,
• W. Sheridan,
• A. Risitano

Affiliations

A. McDonald

1 Netcare Pretoria East Hospital, Moreleta Park

J. L. R. Malherbe

2 University of the Free State, Bloemfontein, South Africa

A. Kulasekararaj

3 Kings College Hospital NHS Foundation Trust, London, United Kingdom

W. Füreder

4 Medical University of Vienna, Vienna, Austria

M. Griffin

5 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

M. Cornpropst

6 BioCryst Pharmaceuticals, Durham, United States of America

M. K. Farmer

6 BioCryst Pharmaceuticals, Durham, United States of America

D. Kargl

6 BioCryst Pharmaceuticals, Durham, United States of America

D. Collins

6 BioCryst Pharmaceuticals, Durham, United States of America

W. Sheridan

6 BioCryst Pharmaceuticals, Durham, United States of America

A. Risitano

7 AORN Moscati, Avellino, Italy